Alzheon IPO To Fund New Phase III Trialling Of Failed Alzheimer's Drug

19 Mar 2018

• By Sten Stovall

Alzheon tells prospective investors it believes beta-amyloid blocker ALZ-801 can succeed in pivotal trials by treating APOE4 subgroup.

SC1803_Alzheimers_677117209 _1200.jpg — Alzheon May Need Higher IPO Funding Target If Extra Alzheimer's Trial Needed • Source: Shutterstock

Alzheon Inc. believes the reworked active ingredient of its in-licensed compound ALZ-801 can prove a success in treating a subset of Alzheimer's disease patients, and plans a NASDAQ listing to raise the funds for a Phase III clinical trial set to start later this year.

But the preliminary funing target of $80m may not be enough to get the drug approved if FDA isn't content with just one pivotal

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.